Primary biliary cirrhosis- Pipeline Insight, 2025
Description
DelveInsight’s, “Primary biliary cirrhosis- Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Primary biliary cirrhosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Primary biliary cirrhosis: Overview
Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease of autoimmune etiology characterized by injury of the intrahepatic bile ducts that may eventually lead to liver failure. Affected individuals are usually in their fifth to seventh decades of life at time of diagnosis, and 90% are women. Annual incidence is estimated between 0.7 and 49 cases per million-population and prevalence between 6.7 and 940 cases per million-population (depending on age and sex). PBC does not always cause symptoms, but some people may experience: bone and joint aches, fatigue (extreme tiredness), itchy skin, dry eyes and mouth, pain or discomfort in the upper right side of their tummy. The majority of patients are asymptomatic at diagnosis, however, some patients present with symptoms of fatigue and/or pruritus. Patients may even present with ascites, hepatic encephalopathy and/or esophageal variceal hemorrhage. Genetic susceptibility as a predisposing factor for PBC has been suggested. Environmental factors may have potential causative role (infection, chemicals, smoking). Diagnosis is based on a combination of clinical features, abnormal liver biochemical pattern in a cholestatic picture persisting for more than six months and presence of detectable antimitochondrial antibodies (AMA) in serum. All AMA negative patients with cholestatic liver disease should be carefully evaluated with cholangiography and liver biopsy. Ursodeoxycholic acid (UDCA) is the only currently known medication that can slow the disease progression.
""Primary biliary cirrhosis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Primary biliary cirrhosis pipeline landscape is provided which includes the disease overview and Primary biliary cirrhosis treatment guidelines. The assessment part of the report embraces, in depth Primary biliary cirrhosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary biliary cirrhosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Primary biliary cirrhosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Primary biliary cirrhosis Emerging Drugs
Further product details are provided in the report……..
Primary biliary cirrhosis: Therapeutic Assessment
This segment of the report provides insights about the different Primary biliary cirrhosis drugs segregated based on following parameters that define the scope of the report, such as:
Primary biliary cirrhosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Primary biliary cirrhosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Primary biliary cirrhosis drugs.
Primary biliary cirrhosis Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Primary biliary cirrhosis: Overview
Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease of autoimmune etiology characterized by injury of the intrahepatic bile ducts that may eventually lead to liver failure. Affected individuals are usually in their fifth to seventh decades of life at time of diagnosis, and 90% are women. Annual incidence is estimated between 0.7 and 49 cases per million-population and prevalence between 6.7 and 940 cases per million-population (depending on age and sex). PBC does not always cause symptoms, but some people may experience: bone and joint aches, fatigue (extreme tiredness), itchy skin, dry eyes and mouth, pain or discomfort in the upper right side of their tummy. The majority of patients are asymptomatic at diagnosis, however, some patients present with symptoms of fatigue and/or pruritus. Patients may even present with ascites, hepatic encephalopathy and/or esophageal variceal hemorrhage. Genetic susceptibility as a predisposing factor for PBC has been suggested. Environmental factors may have potential causative role (infection, chemicals, smoking). Diagnosis is based on a combination of clinical features, abnormal liver biochemical pattern in a cholestatic picture persisting for more than six months and presence of detectable antimitochondrial antibodies (AMA) in serum. All AMA negative patients with cholestatic liver disease should be carefully evaluated with cholangiography and liver biopsy. Ursodeoxycholic acid (UDCA) is the only currently known medication that can slow the disease progression.
""Primary biliary cirrhosis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Primary biliary cirrhosis pipeline landscape is provided which includes the disease overview and Primary biliary cirrhosis treatment guidelines. The assessment part of the report embraces, in depth Primary biliary cirrhosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary biliary cirrhosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Primary biliary cirrhosis R&D. The therapies under development are focused on novel approaches to treat/improve Primary biliary cirrhosis.
This segment of the Primary biliary cirrhosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Primary biliary cirrhosis Emerging Drugs
- Elafibranor: Genfit
- Seladelpar: CymaBay Therapeutics
- Setanaxib: Calliditas Therapeutics
Further product details are provided in the report……..
Primary biliary cirrhosis: Therapeutic Assessment
This segment of the report provides insights about the different Primary biliary cirrhosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Primary biliary cirrhosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Primary biliary cirrhosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Primary biliary cirrhosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Primary biliary cirrhosis drugs.
Primary biliary cirrhosis Report Insights
- Primary biliary cirrhosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Primary biliary cirrhosis drugs?
- How many Primary biliary cirrhosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Primary biliary cirrhosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Primary biliary cirrhosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Primary biliary cirrhosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Genfit
- CymaBay Therapeutics
- Calliditas Therapeutics
- Zydus-Cadila
- Chia Tai Tianqing Pharmaceutical Group
- Cour Pharmaceutical Development
- Ascletis
- Novartis
- Mirum Pharmaceuticals
- Intercept Pharmaceuticals
- HighTide Biopharma
- PRISM Pharma Co
- GlaxoSmithKline
- Elafibranor
- Seladelpar
- Setanaxib
- Bilypsa
- TQA3526
- CNP-104
- ASC42
- LJN-452
- Volixibat
- Bezafibrate
- HTD1801
- OP-724
- Linerixibat
Table of Contents
120 Pages
- Introduction
- Executive Summary
- Primary biliary cirrhosis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Primary biliary cirrhosis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Elafibranor: Genfit
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Primary biliary cirrhosis Key Companies
- Primary biliary cirrhosis Key Products
- Primary biliary cirrhosis- Unmet Needs
- Primary biliary cirrhosis- Market Drivers and Barriers
- Primary biliary cirrhosis- Future Perspectives and Conclusion
- Primary biliary cirrhosis Analyst Views
- Primary biliary cirrhosis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
